Autoimmune disease
MONDO:0007179A disorder resulting from loss of function or tissue destruction of an organ or multiple organs, arising from humoral or cellular immune responses of the individual to their own tissue constituents. It may be systemic (e.g., systemic lupus erythematosus), or organ specific, (e.g., thyroiditis).
Also known as: autoimmune disease, autoimmune disease or disorder, autoimmune disorder, disease, autoimmune, autoimmune hypersensitivity disease, hypersensitivity reaction type II disease
4049 clinical trials for this condition and its sub-types, 315 tagged with Autoimmune disease itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Autoimmune disease
-
Autoimmune disorder of the nervous system 47 trials · 1,067 incl. sub-types
4 sub-types
- Autoimmune disorder of central nervous system 2 trials · 881 incl. sub-types Sub-types →
- Autoimmune disorder of peripheral nervous system 0 trials · 195 incl. sub-types Sub-types →
- Pediatric acute-onset neuropsychiatric syndrome 8 trials · 10 incl. sub-types Sub-types →
- Autoimmune retinopathy 0 trials
-
Autoimmune disorder of gastrointestinal tract 0 trials · 942 incl. sub-types
7 sub-types
- Type 1 diabetes mellitus 819 trials · 820 incl. sub-types Sub-types →
- Celiac disease 81 trials Sub-types →
- Autoimmune hepatitis 30 trials · 31 incl. sub-types Sub-types →
- Autoimmune enteropathy 2 trials · 11 incl. sub-types Sub-types →
- Autoimmune gastritis 3 trials
- Autoimmune pancreatitis 3 trials Sub-types →
- IgG4-related sclerosing cholangitis 0 trials
-
Autoimmune disorder of endocrine system 1 trial · 929 incl. sub-types
13 sub-types
- Type 1 diabetes mellitus 819 trials · 820 incl. sub-types Sub-types →
- Autoimmune thyroid disease 8 trials · 62 incl. sub-types Sub-types →
- Autoimmune hepatitis 30 trials · 31 incl. sub-types Sub-types →
- Autoimmune polyendocrinopathy 3 trials · 11 incl. sub-types Sub-types →
- Immune dysregulation-polyendocrinopathy-enteropathy-X-linked syndrome 10 trials
- Autoimmune hypoparathyroidism 0 trials · 8 incl. sub-types Sub-types →
- Autoimmune pancreatitis 3 trials Sub-types →
- Autoimmune primary ovarian failure 1 trial
- IgG4-related sclerosing cholangitis 0 trials
- Autoimmune enteropathy and endocrinopathy - susceptibility to chronic infections syndrome 0 trials
- Autoimmune oophoritis 0 trials
- Insulin autoimmune syndrome 0 trials
- Primary hypophysitis 0 trials Sub-types →
-
CNS demyelinating autoimmune disease 5 trials · 859 incl. sub-types
1 sub-type
- Multiple sclerosis 770 trials · 858 incl. sub-types Sub-types →
-
Autoimmune disorder of musculoskeletal system 0 trials · 797 incl. sub-types
3 sub-types
- Rheumatoid arthritis 578 trials · 797 incl. sub-types Sub-types →
- Autoimmune cardiomyopathy 0 trials Sub-types →
- Neonatal dermatomyositis 0 trials
-
Lupus erythematosus 40 trials · 551 incl. sub-types
3 sub-types
- Systemic lupus erythematosus 518 trials · 524 incl. sub-types Sub-types →
- Cutaneous lupus erythematosus 38 trials · 46 incl. sub-types Sub-types →
- Drug-induced lupus erythematosus 1 trial
-
Scleroderma 47 trials · 305 incl. sub-types
3 sub-types
- Systemic sclerosis 261 trials · 295 incl. sub-types Sub-types →
- Localized scleroderma 14 trials · 15 incl. sub-types Sub-types →
- Neonatal scleroderma 0 trials
-
Autoimmune disorder of exocrine system 0 trials · 197 incl. sub-types
3 sub-types
- Sjogren syndrome 167 trials
- Autoimmune hepatitis 30 trials · 31 incl. sub-types Sub-types →
- Benign lymphoepithelial lesion of salivary gland 0 trials
-
Autoimmune disorder of blood 0 trials · 152 incl. sub-types
2 sub-types
- Primary thrombocytopenia 27 trials · 110 incl. sub-types Sub-types →
- Autoimmune hemolytic anemia 49 trials · 72 incl. sub-types Sub-types →
-
Autoimmune thrombocytopenia 8 trials · 113 incl. sub-types
2 sub-types
- Autoimmune thrombocytopenic purpura 95 trials
- Evans syndrome 19 trials
-
Vitiligo 100 trials
3 sub-types
- Generalized vitiligo 16 trials
- Alopecia universalis onychodystrophy vitiligo 0 trials
- Trichrome vitiligo 0 trials
-
Antiphospholipid syndrome 58 trials · 59 incl. sub-types
4 sub-types
- Primary antiphospholipid syndrome 4 trials
- Catastrophic antiphospholipid syndrome 1 trial
- Familial antiphospholipid syndrome 0 trials
- Secondary antiphospholipid syndrome 0 trials Sub-types →
-
Autoimmune bullous skin disease 7 trials · 56 incl. sub-types
11 sub-types
- Pemphigus 20 trials · 28 incl. sub-types Sub-types →
- Bullous pemphigoid 18 trials
- Mucous membrane pemphigoid 5 trials · 9 incl. sub-types Sub-types →
- Acquired epidermolysis bullosa 3 trials
- Dermatitis herpetiformis 1 trial Sub-types →
- Pemphigoid 1 trial
- IgA pemphigus 0 trials
- Anti-p200 pemphigoid 0 trials
- Linear IgA Dermatosis 0 trials
- Paraneoplastic pemphigus 0 trials
- Subcorneal pustular dermatosis 0 trials
-
Immunoglobulin G4-related sclerosing disease 30 trials · 34 incl. sub-types
14 sub-types
- Autoimmune pancreatitis 3 trials Sub-types →
- IgG4-related kidney disease 1 trial
- IgG4-related retroperitoneal fibrosis 1 trial Sub-types →
- IgG4-related aortitis 0 trials
- IgG4-related mediastinitis 0 trials
- IgG4-related mesenteritis 0 trials
- IgG4-related ophthalmic disorder 0 trials Sub-types →
- IgG4-related pachymeningitis 0 trials
- IgG4-related sclerosing cholangitis 0 trials
- IgG4-related submandibular gland disease 0 trials
- IgG4-related thyroid disease 0 trials
- Cutaneous pseudolymphoma 0 trials
- Eosinophilic angiocentric fibrosis 0 trials
- Primary cutaneous plasmacytosis 0 trials
-
Rheumatic fever 17 trials
-
Overlapping connective tissue disease 2 trials · 15 incl. sub-types
2 sub-types
- Mixed connective tissue disease 15 trials
- MASS syndrome 0 trials
-
Autoimmune lymphoproliferative syndrome 11 trials · 12 incl. sub-types
9 sub-types
- Autoimmune lymphoproliferative syndrome type 4 3 trials
- FAS-related autoimmune lymphoproliferative syndrome 2 trials
- Autoimmune lymphoproliferative syndrome due to CTLA4 haploinsufficiency 1 trial
- Castleman-Kojima disease 0 trials
- Autoimmune lymphoproliferative syndrome type 1 0 trials
- Autoimmune lymphoproliferative syndrome type 2A 0 trials
- Autoimmune lymphoproliferative syndrome type 2B 0 trials
- Autoimmune lymphoproliferative syndrome, type III caused by mutation in PRKCD 0 trials
- Type 3 autoimmune lymphoproliferative syndrome 0 trials
-
Type III hypersensitivity disease 3 trials · 6 incl. sub-types
2 sub-types
- Serum sickness 3 trials
- Arthus reaction 0 trials
-
Autoimmune disease of ear, nose and throat 0 trials · 4 incl. sub-types
7 sub-types
- Autoimmune inner ear disease 2 trials
- Autoimmune uveitis 2 trials
- Cogan syndrome 0 trials
- IgG4-related dacryoadenitis and sialadenitis 0 trials
- IgG4-related submandibular gland disease 0 trials
- Autoimmune retinopathy 0 trials
- Eosinophilic angiocentric fibrosis 0 trials
-
Cryoglobulinemia 3 trials
1 sub-type
- Cryofibrinogenemia 0 trials Sub-types →
-
Autoimmune disorder of cardiovascular system 0 trials · 3 incl. sub-types
6 sub-types
- Chilblain lupus 1 trial · 3 incl. sub-types Sub-types →
- Libman-Sacks endocarditis 0 trials
- Autoimmune atherosclerosis 0 trials
- Autoimmune cardiomyopathy 0 trials Sub-types →
- Autoimmune vasculitis 0 trials Sub-types →
- Rheumatic pulmonary valve disease 0 trials
-
Susac syndrome 2 trials
-
Autoimmune disease, multisystem, infantile-onset 0 trials · 2 incl. sub-types
-
Phacolytic glaucoma 1 trial
-
Secondary neonatal autoimmune disease 0 trials · 1 incl. sub-types
6 sub-types
- Neonatal lupus erythematosus 1 trial
- Neonatal antiphospholipid syndrome 0 trials
- Neonatal autoimmune hemolytic anemia 0 trials
- Neonatal dermatomyositis 0 trials
- Neonatal scleroderma 0 trials
- Transient neonatal myasthenia gravis 0 trials
-
Jaccoud syndrome 0 trials
-
Kimura disease 0 trials
-
Reynolds syndrome 0 trials
-
Autoimmune glomerulonephritis 0 trials
-
Autoimmune urticaria 0 trials
-
Euthyroid Graves orbitopathy 0 trials
-
Tempi syndrome 0 trials
Most studied deeper sub-types
-
New pill could tame lupus flares in major trial
Disease control OngoingThis phase 3 trial tests whether adding cenerimod, a daily pill, to standard lupus treatments can reduce symptoms in adults with moderate-to-severe systemic lupus erythematosus (SLE). About 470 participants will receive either cenerimod or a placebo for 12 months. Researchers wil…
Phase 3 • Sponsor: Viatris Innovation GmbH • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New lupus pill shows promise in major trial
Disease control OngoingThis Phase 3 study tests whether adding cenerimod to standard lupus treatments can better control moderate-to-severe lupus symptoms. About 451 adults will receive either cenerimod or a placebo for 12 months. The main goal is to see if more people improve on a lupus disease activi…
Phase 3 • Sponsor: Viatris Innovation GmbH • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Can a Blood-Cleaning device hit its plasma exchange targets?
Disease control OngoingResearchers review past therapeutic plasma exchange treatments performed with the multiFiltratePRO, a device that cleans blood outside the body. The study looks at records from people with autoimmune diseases who weighed at least 40 kg and received this treatment between 2019 and…
Sponsor: Fresenius Medical Care Deutschland GmbH • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New stem cell transplant trial aims to control tough lymphoma
Disease control OngoingThis study tests a stem cell transplant to control peripheral T-cell lymphoma in people whose cancer has not responded to standard treatments. Participants receive a donor's stem cells after chemotherapy or antibody therapy to prepare their body. The goal is to see if this approa…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New lupus drug tested for Long-Term safety in 680 patients
Disease control By invitation onlyThis study looks at the long-term safety of cenerimod in adults with moderate-to-severe lupus. About 680 participants who were in a previous study will take cenerimod for up to 3 years, along with their usual lupus medications. Researchers will track side effects and see how well…
Phase 3 • Sponsor: Viatris Innovation GmbH • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New drug aims to tame scleroderma in major trial
Disease control OngoingThis Phase 3 study tests whether anifrolumab, given as a weekly shot, can improve symptoms of systemic sclerosis (scleroderma) compared to a placebo. About 314 adults aged 18-70 with early-stage disease will take part. The main goal is to see if more people respond to treatment, …
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
New drug hope for scleroderma patients with lung complications
Disease control OngoingThis study tests an experimental drug called ifetroban in 34 adults with a severe form of scleroderma (diffuse cutaneous systemic sclerosis) or scleroderma-related lung disease (pulmonary arterial hypertension). The main goal is to see if the drug is safe and whether it can impro…
Phase 2 • Sponsor: Cumberland Pharmaceuticals • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New study tests belimumab to tame early lupus
Disease control OngoingThis study is testing the drug belimumab (Benlysta) in 350 adults who were diagnosed with systemic lupus erythematosus (SLE) within the last two years and still have active disease despite standard treatment. The goal is to see if adding belimumab helps more people reach a state …
Phase 4 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New lupus drug afimetoran enters Mid-Stage trial
Disease control OngoingThis phase 2 trial tests whether the drug afimetoran can safely control active systemic lupus erythematosus (SLE) better than a placebo. About 268 participants with lupus will receive either afimetoran or a placebo for 48 weeks, with an extension period allowing placebo users to …
Phase 2 • Sponsor: Beeline Medicines Corporation • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
New lupus pill shows promise in Mid-Stage trial
Disease control OngoingThis Phase 2 study tests an experimental oral drug called ESK-001 in 408 adults with active systemic lupus erythematosus (SLE). Participants receive either ESK-001 or a placebo for 48 weeks to see if the drug can reduce disease activity. The goal is to find a new treatment option…
Phase 2 • Sponsor: Alumis Inc • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
New antibody drug aims to halt Scleroderma's damage
Disease control OngoingThis Phase 2 trial tests a drug called tibulizumab in 80 adults with systemic sclerosis, a disease that causes skin thickening and can damage organs. Participants first receive either the drug or a placebo for 24 weeks, then everyone who continues gets the drug for another 28 wee…
Phase 2 • Sponsor: Zura Bio Inc • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Could a week of antibiotics stop joint infections after replacement surgery?
Disease control By invitation onlyThis study tests whether taking a 7-day course of oral antibiotics after hip or knee replacement surgery can prevent joint infections in patients at higher risk due to conditions like obesity, diabetes, or autoimmune disease. About 4,600 participants will receive one of three ant…
Phase 4 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Experimental CAR-T therapy targets tough autoimmune conditions
Disease control PausedThis early-phase study tests a new type of CAR-T cell therapy in 9 people with autoimmune diseases that have not responded well to standard treatments. The therapy uses specially engineered immune cells to target and attack faulty immune cells. The main goal is to check safety an…
Early phase 1 • Sponsor: Beijing Boren Hospital • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
MS trial withdrawn before it began: CAR T-Cell hope on hold
Disease control CancelledThis study aimed to test a new treatment called CABA-201, a CAR T-cell therapy made from a patient's own immune cells, for people with multiple sclerosis (MS). The goal was to see if it was safe and could control the disease by targeting and resetting the immune system. However, …
Phase 1/2 • Sponsor: Cabaletta Bio • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Can magnetic waves tame autoimmune disease? new trial begins
Disease control By invitation onlyThis study tests a non-invasive device that uses low-frequency electromagnetic fields to improve communication between immune cells. 120 adults with lupus, rheumatoid arthritis, or multiple sclerosis will receive either active or sham sessions three times a week for 12 weeks. The…
Phase 1/2 • Sponsor: Truway Health, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New shot could help when arthritis drugs fail
Disease control OngoingThis study tests a new drug called IMVT-1402 in 120 adults with active, difficult-to-treat rheumatoid arthritis. Participants receive weekly injections of either the drug or a placebo. The goal is to see if the drug helps maintain symptom improvement over 28 weeks.
Phase 2 • Sponsor: Immunovant Sciences GmbH • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New drug combo shows promise for rare blood disorder
Disease control OngoingThis study tests whether adding eltrombopag to standard immunosuppressive therapy can improve blood cell counts in people with untreated severe aplastic anemia. Participants receive horse-ATG and cyclosporine plus eltrombopag for up to 6 months. The goal is to see if this combina…
Phase 1/2 • Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Can a new immune system fix T-Cell diseases? trial tests donor transplants
Disease control OngoingThis study tests whether a stem cell transplant from a healthy donor can safely treat people with severe T-cell problems. Participants receive chemotherapy and antibody therapy before the transplant, followed by donor stem cells. The goal is to see if the new immune system can co…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Engineered immune cells take on lupus and scleroderma in early trial
Disease control By invitation onlyThis early-phase study tests a new treatment called Prula-cel for people with autoimmune diseases like lupus, scleroderma, and vasculitis. Prula-cel uses donor immune cells engineered to target and destroy faulty immune cells that attack the body. The goal is to find a safe dose …
Phase 1 • Sponsor: Adicet Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New shot could tame Sjögren's Flare-Ups
Disease control OngoingThis Phase 2 trial tests whether sibeprenlimab, a biologic drug given as a shot every 4 weeks, can reduce disease activity and symptoms in people with Sjögren's disease. About 83 adults with moderate-to-active disease will receive either the drug or a placebo, added to their usua…
Phase 2 • Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
Could a stem cell transplant stop the immune system from attacking the brain?
Disease control OngoingThis phase 2 trial tests whether high-dose chemotherapy followed by a stem cell transplant can stop the immune system from attacking the nervous system in people with autoimmune neurologic diseases like multiple sclerosis and stiff person syndrome. The treatment aims to weaken th…
Phase 2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New biologic shot aims to tame painful skin disease
Disease control OngoingThis early-stage trial tests a single dose of a new biologic drug, SBT777101, in 24 adults with moderate-to-severe hidradenitis suppurativa (a chronic skin condition causing painful abscesses and tunnels). The main goal is to check safety and side effects at increasing dose level…
Phase 1 • Sponsor: Sonoma Biotherapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Could CAR-T cells tame autoimmune diseases? early trial begins
Disease control PausedThis early-phase trial is testing a CAR-T cell therapy called RD06-04 in 12 people with active autoimmune diseases like lupus, scleroderma, and vasculitis. The treatment involves reprogramming a patient's own immune cells to target and destroy faulty B cells. The main goal is to …
Early phase 1 • Sponsor: Nanjing Bioheng Biotech Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
Withdrawn before start: experimental cocktail for type 1 diabetes never tested
Disease control CancelledThis pilot study aimed to test whether a combination of four drugs—ATG, low-dose IL-2, adalimumab, and exenatide—could help people newly diagnosed with type 1 diabetes keep producing their own insulin. The trial planned to enroll adults aged 18-35 diagnosed within the last 120 da…
Phase 1/2 • Sponsor: Camillo Ricordi and Jay Skyler • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
Engineered immune cells take on lupus and scleroderma in first human test
Disease control OngoingThis early-stage study is testing a new treatment called CNTY-101 for people with severe autoimmune diseases like lupus, scleroderma, and inflammatory myopathies that haven't improved with standard therapies. CNTY-101 uses specially engineered immune cells to target and destroy f…
Phase 1 • Sponsor: Century Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
New drug could slow kidney failure in IgA nephropathy patients
Disease control OngoingThis study tests a drug called telitacicept in 318 adults with IgA nephropathy, a kidney disease that can lead to kidney failure. Participants are at high risk of worsening despite standard blood pressure medications. The goal is to see if telitacicept can reduce protein in the u…
Phase 3 • Sponsor: RemeGen Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
New lupus pill shows promise in major trial
Disease control OngoingThis study tests whether the drug deucravacitinib can safely control symptoms in people with active moderate-to-severe lupus. About 513 participants will receive either the drug or a placebo. The goal is to see if the drug reduces lupus disease activity better than placebo.
Phase 3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
New pill could tame lupus flares
Disease control OngoingThis Phase 3 trial tests whether the oral drug deucravacitinib can safely control moderate to severe lupus better than a placebo. About 516 adults with active lupus are taking either the drug or a dummy pill for several months. The goal is to see if the drug reduces lupus symptom…
Phase 3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
Experimental Donor-Cell therapy takes aim at tough autoimmune diseases
Disease control OngoingThis early-stage study tests a therapy called SC291, made from donor immune cells, in 7 people with severe lupus or vasculitis that hasn't improved with standard treatments. The goal is to see if it is safe and tolerable, and to get a first look at whether it can control the dise…
Phase 1 • Sponsor: Sana Biotechnology • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
Stem cell shot aims to tame rheumatoid arthritis
Disease control OngoingThis early-phase trial tests a single intravenous infusion of stem cells from donated umbilical cords (BC-U001) in 9 adults with moderate-to-severe rheumatoid arthritis who haven't responded well to standard treatments. The main goal is to check safety and find the right dose, wh…
Phase 1/2 • Sponsor: Beijing Baylx Biotech Co., Ltd. • Aim: Disease control
Last updated Jun 26, 2026 18:51 UTC
-
Gene-Edited cell therapy for lupus trial pulled before it started
Disease control CancelledThis early-stage study aimed to test a single infusion of CB-010, a CRISPR-edited CAR-T cell therapy made from donor cells, in people with severe lupus that did not respond to standard treatments. The trial was withdrawn before enrolling any participants, so no results are availa…
Phase 1 • Sponsor: Caribou Biosciences, Inc. • Aim: Disease control
Last updated Jun 26, 2026 18:51 UTC
-
Promising ITP drug trial pulled before it even started
Disease control CancelledThis study was designed to test the safety and tolerability of a new drug called HMPL-523 (sovleplenib) in adults with immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding problems. The trial was withdrawn before enrolling any pa…
Phase 1 • Sponsor: Hutchmed • Aim: Disease control
Last updated Jun 26, 2026 18:23 UTC
-
Could your own belly fat help fight MS?
Disease control PausedThis study tests whether a patient's own fat cells, processed into a special mixture called stromal vascular fraction, can safely improve quality of life and slow nerve damage in multiple sclerosis. About 100 adults with stable MS who have lasting nerve problems will receive an I…
Sponsor: Healeon Medical Inc • Aim: Disease control
Last updated Jun 26, 2026 15:54 UTC
-
Can a single platform predict your risk for multiple chronic diseases?
Diagnosis By invitation onlyThis pilot study is testing whether the ADEN platform can accurately identify people at risk for heart disease, respiratory problems, cancer, autoimmune conditions, and frailty. Researchers will compare the platform's risk ratings to those made by doctors. If it works, the platfo…
Sponsor: Unidad de Investigación Genética Molecular • Aim: Diagnosis
Last updated Jul 29, 2026 00:00 UTC
-
New MRI clue could slash MS misdiagnosis rates
Diagnosis OngoingThis study is testing whether a specific feature on brain MRI scans—called the central vein sign—can improve the accuracy of multiple sclerosis (MS) diagnosis. Currently, up to 1 in 5 people diagnosed with MS are later found not to have the disease, leading to unnecessary and pot…
Sponsor: The Cleveland Clinic • Aim: Diagnosis
Last updated Jun 27, 2026 07:52 UTC
-
Could a simple injection stop type 1 diabetes before it starts?
Prevention OngoingThis phase II trial tests a drug called Diamyd, given as injections into lymph nodes, to see if it is safe and can prevent type 1 diabetes in children aged 8 to 17 who are at high risk. Only 5 participants are enrolled, and the study focuses on safety and whether the drug can sto…
Phase 2 • Sponsor: Diamyd Medical AB • Aim: Prevention
Last updated Jun 27, 2026 12:10 UTC
-
Low-gluten diet in toddlers may cut celiac risk, study finds
Prevention OngoingThis study looks at whether giving children with a genetic risk for celiac disease a low-gluten diet (less than 3 grams per day) during their first three years of life can lower their chance of developing the disease by age 7. About 1,100 children from Sweden are taking part. The…
Sponsor: Lund University • Aim: Prevention
Last updated Jun 27, 2026 12:06 UTC
-
Cancer cell therapy recipients monitored for years in new safety study
Knowledge-focused By invitation onlyThis study follows 1,000 people who previously received gene-modified cell therapies (like Yescarta or Tecartus) for blood or solid cancers. No new treatment is given. Researchers will watch for late side effects, growth in children, and overall survival. The goal is to better un…
Sponsor: Kite, A Gilead Company • Aim: Knowledge-focused
Last updated Sep 21, 2026 15:00 UTC
-
New blood test could spot autoimmune diseases earlier
Knowledge-focused By invitation onlyThis study will use a special blood test called mass spectrometry to look at immune cells in 500 people with various autoimmune diseases and healthy volunteers. The goal is to find patterns that could help doctors diagnose these conditions sooner. No treatments are being tested; …
Sponsor: Peking University People's Hospital • Aim: Knowledge-focused
Last updated Aug 28, 2026 00:00 UTC
-
New tool could predict who will suffer from steroid side effects
Knowledge-focused OngoingThis study aims to create a tool that predicts which patients with inflammatory rheumatic diseases (like rheumatoid arthritis, vasculitis, or polymyalgia rheumatica) will develop serious side effects from long-term steroid use. Researchers will collect routine medical data—such a…
Sponsor: University Hospital, Brest • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
Massive italian MS registry aims to unlock secrets of the disease
Knowledge-focused By invitation onlyThis observational study is creating a large database of up to 96,000 people with multiple sclerosis and related conditions in Italy. Researchers will collect information on patient demographics, treatments, and disease progression over time. The goal is to better understand thes…
Sponsor: Fondazione Italiana Sclerosi Multipla • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:05 UTC
-
Researchers hunt for clues: do our own antibodies harm nerves?
Knowledge-focused By invitation onlyThis study looks at whether the immune system mistakenly makes antibodies that attack the body's own nerves and muscles in people with multiple sclerosis, myasthenia gravis, and similar conditions. Researchers will collect blood samples (and sometimes cheek swabs) from 120 adults…
Sponsor: University of California, Davis • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:34 UTC
-
Doctor education may boost use of cheaper biologic drugs
Knowledge-focused OngoingThis study looks at whether offering doctors educational meetings about biosimilar medications leads them to prescribe more of these lower-cost alternatives instead of the original brand-name drugs. About 1,325 clinicians who prescribe adalimumab for conditions like rheumatoid ar…
Sponsor: Brigham and Women's Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:34 UTC
-
New registry aims to unlock safer pregnancies for women with autoimmune conditions
Knowledge-focused By invitation onlyThis registry enrolls up to 1,000 women aged 12–55 with rheumatic or autoimmune diseases who are pregnant or planning pregnancy. Researchers will collect data from medical records and patient surveys to study pregnancy outcomes, disease activity, and medication use. No experiment…
Sponsor: Duke University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:30 UTC
-
Immune cell showdown: autoimmune vs. infection vs. healthy
Knowledge-focused By invitation onlyThis study looks at immune cells from people with autoimmune diseases (like lupus), people with infections, and healthy volunteers. Researchers want to understand how these cells differ and what makes them attack the body in autoimmune conditions. The study involves blood and bon…
Sponsor: Emory University • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:53 UTC
-
Brain fog after hip or knee replacement: how common and how long?
Knowledge-focused OngoingThis study follows 505 adults aged 50 and older who are having hip or knee replacement surgery. Researchers use a simple online card-game test to measure changes in memory, attention, and thinking before and up to 4.5 months after surgery. The goal is to find out how many people …
Sponsor: Dr. Stephen Choi • Aim: Knowledge-focused
Last updated Jun 26, 2026 14:02 UTC